Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2–<18 Year Olds
Julia R. Glanternik(Pfizer (United States)), Iona Munjal(Pfizer (United States)), Lisa Steffany Pinheiro Pereira(Pfizer (United States)), Elie Needle(Pfizer (United States)), Grant Paulsen(Cincinnati Children's Hospital Medical Center), Shelly Senders(SUNY Upstate Medical University), Danielle Baranova(Pfizer (United States)), Lesong Chen(Pfizer (United States)), Alejandra Gurtman(Johns Hopkins University), Emma Shittu(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), David Cooper(Johns Hopkins University), MaryAnn Murillo(Pfizer (United States)), Kena A Swanson(Pfizer (United States)), John M. Leech(Pfizer (United States)), Maria Maddalena Lino(Pfizer (United States)), Annaliesa S. Anderson(Pfizer (United States)), Elena Kalinina(Pfizer (United States))
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937